| scholarly article | Q13442814 |
| P50 | author | Jean-Yves Blay | Q37842284 |
| Vanja Sisirak | Q40929664 | ||
| Jacqueline Marvel | Q42835561 | ||
| Christophe Caux | Q56528905 | ||
| Nathalie Bendriss-Vermare | Q89821707 | ||
| Isabelle Treilleux | Q114340573 | ||
| Isabelle Durand | Q115705884 | ||
| Nadège Goutagny | Q117275057 | ||
| P2093 | author name string | Isabelle Puisieux | |
| Isabelle Le Mercier | |||
| Michael Gobert | |||
| Bertrand Dubois | |||
| Jaromir Vlach | |||
| Dominique Poujol | |||
| Amélien Sanlaville | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| dendritic cell | Q506253 | ||
| Tumor promotion | Q7852681 | ||
| P304 | page(s) | 4629-4640 | |
| P577 | publication date | 2013-05-30 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment | |
| P478 | volume | 73 |
| Q34398859 | Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. |
| Q89450094 | Application of antigen presenting cell-targeted nanovaccine delivery system in rhabdovirus disease prophylactics using fish as a model organism |
| Q90893993 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies |
| Q64253586 | Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? |
| Q64886488 | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. |
| Q57480337 | Biomaterials for vaccine-based cancer immunotherapy |
| Q37605221 | Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. |
| Q38994017 | Dendritic Cells and Cancer Immunity. |
| Q38786002 | Dendritic Cells in the Context of Human Tumors: Biology and Experimental Tools |
| Q27012618 | Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models |
| Q27000318 | Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment |
| Q38963934 | Dendritic cells in cancer: the role revisited |
| Q37456825 | Dendritic cells, inflammation, and breast cancer |
| Q43930865 | Disease-Associated Plasmacytoid Dendritic Cells |
| Q35506268 | Dual roles of TLR7 in the lung cancer microenvironment |
| Q34469457 | Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells |
| Q28085563 | Engineering New Approaches to Cancer Vaccines |
| Q92071975 | Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells |
| Q38930365 | HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells |
| Q90441910 | Harnessing innate immunity in cancer therapy |
| Q89698021 | Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma |
| Q92316756 | Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses |
| Q36821232 | Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. |
| Q93104527 | Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review |
| Q42378527 | Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy |
| Q58553701 | In vivo cancer vaccination: Which dendritic cells to target and how? |
| Q50217779 | Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment |
| Q37691837 | Intratumoral immunization: a new paradigm for cancer therapy |
| Q92385655 | Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response |
| Q37248929 | Many Roles of CCL20: Emphasis on Breast Cancer |
| Q64066398 | MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers |
| Q38271879 | Modes of action of TLR7 agonists in cancer therapy |
| Q38374300 | Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial |
| Q58199388 | Molecular dissection of plasmacytoid dendritic cell activation during a viral infection |
| Q52726024 | Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. |
| Q92435772 | Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer |
| Q64102126 | Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc Monocytes in Rectal Cancer |
| Q41590471 | New role for antigen-presenting activated pDCs in promoting Th17 cells and impacting antitumor immunity |
| Q90390338 | OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity |
| Q54378300 | Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". |
| Q36170378 | Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. |
| Q38294189 | Plasmacytoid dendritic cells, a role in neoplastic prevention and progression |
| Q91982102 | Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses |
| Q57821272 | Recent advances in understanding dendritic cell development, classification, and phenotype |
| Q38714188 | Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor |
| Q48259591 | S1PR4 Signaling Attenuates ILT 7 Internalization To Limit IFN-α Production by Human Plasmacytoid Dendritic Cells. |
| Q52606149 | Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. |
| Q58765498 | Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells |
| Q37706972 | TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo |
| Q58547311 | Targeting macrophages: therapeutic approaches in cancer |
| Q35176307 | Targeting the tumor microenvironment to enhance antitumor immune responses |
| Q64236840 | The Role of Plasmacytoid Dendritic Cells in Gut Health |
| Q98205361 | The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy |
| Q36731249 | The multifaceted biology of plasmacytoid dendritic cells |
| Q92767766 | The p52 isoform of SHC1 is a key driver of breast cancer initiation |
| Q90468281 | Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells |
| Q34438411 | Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ |
| Q36607439 | Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis |
| Q38381929 | Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial |
| Q42867339 | Trial watch: Dendritic cell-based interventions for cancer therapy |
| Q36692838 | Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. |
| Q35798826 | Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. |
| Q38164916 | Tumoricidal activity of human dendritic cells. |
| Q90468303 | Warming up the tumor microenvironment in order to enhance immunogenicity |
Search more.